Author

A. J. Ohnmacht

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:DNA methylation· 1

Frequent Co-Authors

G. Avar· 2 shared M. P. Menden· 2 shared A. Rajamani· 1 shared D. Krappmann· 1 shared D. Saur· 1 shared E. Goncalves· 1 shared G. Kutkaite· 1 shared M. K. Schübel· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Avar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines

A. J. Ohnmacht, G. Avar, M. K. Schübel, T. J. O'Neill, D. Krappmann, M. P. Menden

The paper assesses molecular EMT signatures in cancer cell lines to identify drug susceptibilities, showing EMT can predict responses to HSP90 inhibitors and enhance drug sensitivity through TGF-β stimulation.

bioRxiv · Jan 16, 2024 · PreprintCancer Biology

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity

A. J. Ohnmacht, A. Rajamani, G. Avar, G. Kutkaite, E. Goncalves, D. Saur, M. P. Menden

The paper identifies DNA methylation biomarkers linked to drug sensitivity in cancer cell lines across multiple cancer types and drugs.

bioRxiv · Jun 1, 2023Cancer Biology